VNDA Stock Risk & Deep Value Analysis
Vanda Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VNDA Stock
We analyzed Vanda Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VNDA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is VNDA Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Very High
What Are the Red Flags for VNDA?
- ⚠
Tradipitant Complete Response Letter (CRL) or outright rejection by the FDA
- ⚠
Failure to achieve anticipated sales targets for tradipitant post-approval due to competitive pressures or market adoption challenges
- ⚠
Patent challenges or generic competition for existing products (Hetlioz, Fanapt)
- ⚠
Unexpected safety concerns or adverse events during post-market surveillance of tradipitant
Unlock VNDA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Vanda Pharmaceuticals Inc (VNDA) Do?
Market Cap
$521.23M
Sector
Healthcare
Industry
Biotechnology
Employees
368
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Visit Vanda Pharmaceuticals Inc WebsiteIs VNDA Stock Undervalued?
Unlock the full AI analysis for VNDA
Get the complete DVR score, risk analysis, and more
Does VNDA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The moat is primarily derived from patent protection on existing drugs (Hetlioz) and the potential for a novel mechanism of action with tradipitant. Its durability relies on successful regulatory navigation, market adoption, and ongoing IP defense, which are subject to high uncertainty.
Moat Erosion Risks
- •Failure of tradipitant to gain regulatory approval or achieve significant market share
- •Patent expirations for existing revenue-generating products
- •Emergence of superior or more cost-effective competitor therapies for gastroparesis
VNDA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive VNDA Stock Higher?
Near-Term (0-6 months)
- •Tradipitant FDA PDUFA date announcement for gastroparesis (Expected mid-2026)
- •Q1 2026 Earnings Report (Estimated late April/early May 2026)
- •Any further clinical data readouts or regulatory updates for tradipitant in other indications (e.g., pruritus)
Medium-Term (6-18 months)
- •If approved, initial commercial launch and sales ramp of tradipitant for gastroparesis (H2 2026 - H1 2027)
- •Potential strategic partnerships for ex-US commercialization of tradipitant
- •Pipeline advancement for other early-stage assets
Long-Term (18+ months)
- •Establishing market leadership in gastroparesis with tradipitant
- •Expansion of tradipitant's label to additional indications
- •Sustained revenue growth and profitability driven by new product launches
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VNDA?
- ✓
Official announcement of Tradipitant's PDUFA date or FDA decision
- ✓
Initial sales trajectory and market adoption rates for tradipitant post-approval
- ✓
Any new clinical trial data for tradipitant in other indications or for other pipeline assets
Bull Case Analysis
See what could go right with Premium
Compare VNDA to Similar Stocks
See how Vanda Pharmaceuticals Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VNDA (Vanda Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
